ONC201: Phase I/II started

Oncoceutics began an open-label, U.S. Phase I/II trial to evaluate oral ONC201 every 3 weeks in about 60 patients with relapsed or refractory NHL, including mantle cell lymphoma (MCL), diffuse large B...